deferoxamine has been researched along with 2019 Novel Coronavirus Disease in 3 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abobaker, A | 1 |
| Vlahakos, VD | 1 |
| Marathias, KP | 1 |
| Arkadopoulos, N | 1 |
| Vlahakos, DV | 1 |
| Qaderi, S | 1 |
| Mousavi, SH | 1 |
| Ahmadi, A | 1 |
| Arif, S | 1 |
| Madadi, S | 1 |
| Ayoubi, S | 1 |
| Lucero-Prisno, DE | 1 |
3 other studies available for deferoxamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Neutralizing; Antiviral Agents; B-Lymphocytes; Betaco | 2020 |
Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation?
Topics: Administration, Oral; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Deferoxamine; Hu | 2021 |
Transfusion-dependent beta thalassemia in Afghanistan: current evidence amid COVID-19 and future recommendations.
Topics: Afghanistan; beta-Thalassemia; Blood Donors; Blood Transfusion; Comorbidity; COVID-19; Culturally Co | 2021 |